Vidac Pharma Holding (STU:T9G) Net Margin %: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:T9G Vidac Pharma Holding PLC STU:T9G
21 GF Score
Price €0.42
! 2 Warning Signs
View Full Analysis

What is Vidac Pharma Holding Net Margin %?

Vidac Pharma Holding STU:T9G +1.94% 21 Net Margin % is 0.00% as of Jun. 2025. GuruFocus rates STU:T9G with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Vidac Pharma Holding ranks worse than 105820% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Vidac Pharma Holding's Net Income for the six months ended in Jun. 2025 was €-0.26 Mil. Vidac Pharma Holding's Revenue for the six months ended in Jun. 2025 was €0.00 Mil. Therefore, Vidac Pharma Holding's net margin for the quarter that ended in Jun. 2025 was 0.00%.

The historical rank and industry rank for Vidac Pharma Holding's Net Margin % or its related term are showing as below:


STU:T9G's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -83.18
* Ranked among companies with meaningful Net Margin % only.

Vidac Pharma Holding  (STU:T9G) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Vidac Pharma Holding Net Margin % Related Terms

Vidac Pharma Holding Net Margin % Historical Data

* Premium members only.

The historical data trend for Vidac Pharma Holding's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding Net Margin % Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Margin %
0.00 0.00 0.00 0.00

Vidac Pharma Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Net Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

STU:T9G vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, Vidac Pharma Holding's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's Net Margin % distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's Net Margin % falls into.


STU:T9G
21GF Score
Vidac Pharma Holding PLC STU:T9G
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vidac Pharma Holding Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Vidac Pharma Holding's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-1.673/0
= %

Vidac Pharma Holding's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-0.264/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Vidac Pharma Holding (STU:T9G) has a Net Margin % of 0.00% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Vidac Pharma Holding and its competitors. According to the industry distribution chart, Vidac Pharma Holding ranks #999999 out of 945 companies in the Biotechnology industry.
Is Vidac Pharma Holding's Net Margin % too high?
Vidac Pharma Holding's current Net Margin % is 0.00%. Based on the distribution chart, Vidac Pharma Holding ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vidac Pharma Holding has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Vidac Pharma Holding's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vidac Pharma Holding ranks #999999 out of 945 companies for Net Margin %. This places Vidac Pharma Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vidac Pharma Holding and its competitors. Vidac Pharma Holding's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vidac Pharma Holding stock overvalued right now?
Vidac Pharma Holding (STU:T9G) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Vidac Pharma Holding's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vidac Pharma Holding (STU:T9G), the current Net Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vidac Pharma Holding Business Description

Other Exchanges T9G:Germany
Address 20-22 Wenlock Road, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company that focuses on discovering and developing medicines for oncologic and onco-dermatologic diseases. The company's research targets the modification of the tumor microenvironment to inhibit cancer cell growth by selectively affecting metabolic checkpoints in cancer cells without harming normal tissue. Its drug pipeline includes candidates such as VDA-1102 ointment, VDA-1102 IV, and VDA-1275, which are designed to treat conditions like Actinic Keratosis and Cutaneous T-cell Lymphoma. Vidac Pharma operates internationally with headquarters in London and aims to treat cancer through novel chemical entities.
21GF Score

Get the complete analysis for STU:T9G

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price